TM
Tsveta Milanova
Chief Commercial Officer

Tsveta Milanova insider trades: Agios Pharmaceuticals (AGIO) stock sales

Chief Commercial Officer, Agios Pharmaceuticals Last trade Apr 2, 2026 13 Form 4 filings
$353K
Sold, last 12 months
4 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2023
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Tsveta reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Apr 2, 2026AGIO↓ Sell$113K
Mar 2, 2026AGIO↓ Sell$83K
Jan 5, 2026AGIO↓ Sell$78K
Dec 30, 2025AGIO↓ Sell$79K
Jun 24, 2025AGIO↓ Sell$93K
Mar 3, 2025AGIO↓ Sell$60K
Jan 6, 2025AGIO↓ Sell$90K
Jan 24, 2024AGIO↓ Sell$35K
Jan 5, 2024AGIO↓ Sell$65K
Jun 30, 2023AGIO↓ Sell$46K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other AGIO insiders

Open-market trades in the last 12 months

About Tsveta Milanova's insider trades

Tsveta Milanova is Chief Commercial Officer at Agios Pharmaceuticals (AGIO). Since Jun 30, 2023, Tsveta has reported no open-market purchases and 10 sales worth $742K on SEC Form 4. In the last 12 months: 4 sales ($353K).

Their filings also include option exercises (11 filings), grants and awards (5 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AGIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.